Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Cystic Fibrosis (CF) Patients With Acute Pulmonary Exacerbation (APE) Receiving IV Tobramycin at Risk for Ototoxicity
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Ebselen (Primary)
- Indications Meniere's disease; Sensorineural hearing loss; Tinnitus; Vertigo
- Focus Adverse reactions; Pharmacodynamics
- Acronyms STOP Ototoxicity
- Sponsors Sound Pharmaceuticals
- 30 Jan 2024 According to a Sound Pharmaceuticals Media Release, positive interim data of this trial will be presented at the Association for Research in Otolaryngology (ARO) Midwinter Meeting in Anaheim, CA (February 3-7).
- 30 Jan 2024 Results presented in a Sound Pharmaceuticals Media Release.
- 07 Dec 2022 Planned End Date changed from 1 Dec 2021 to 1 Apr 2023.